** Drugmaker Amgen's AMGN.O shares fall 2.8% to $281 in extended trading
** Company says U.S. FDA placed a clinical hold on an early-stage study for its experimental weight-loss drug AMG 513
** Amgen says discussions are underway on a path forward to reopen the study
** Company posts Q4 adj profit of $5.31/shr vs analysts' average est. of $5.08/shr - LSEG
** Up to last close, stock down 10.2% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.